Conditioning regimens before transplantation in patients with aggressive non-Hodgkin’s lymphoma
Open Access
- 1 February 1998
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 9 (suppl_1) , S15-S21
Abstract
Substantial progress has been made in understanding the role of autotransplantion in aggressivenon-Hodgkin's lymphoma. At present, the clinical indications for high-dose therapy include patients with relapsed or poor prognosis disease. Hematopoietic reconstitution with peripheral stem cells has rendered transplantation less toxic but the optimal preparative regimen remains to be found. It should combine a high antitumor activity with acceptable toxicity to normal tissues. The literature, on combinations of drugs with or without total body irradiation, was reviewed with regard to this objective. BEAM, CBV and ICE, the most common chemotherapy regimens can be considered safe as they cause low transplant-related morbidity. The combination of fractionated TBI and etoposide or cyclophosphamide was not found to be superior. However, it must be kept in mind that comparisons were made on registry data or retrospectively. In every case, relapse of the residual primary disease argue for the need for more effective strategies such as tandem transplantation or sequential high-dose chemotherapy with stem-cell support. To obtain an objective evaluation, these new preparative regimens need to be tested in controlled trials with treatment groups stratified for known prognostic factors.Keywords
This publication has 56 references indexed in Scilit:
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1995
- Dose Intensification of Etoposide in the BEAM ABMT Protocol for Malignant LymphomaLeukemia & Lymphoma, 1995
- Parma international protocol: pilot study of DHAP followed by involved- field radiotherapy and BEAC with autologous bone marrow transplantationBlood, 1991
- The calculation of received dose intensity.Journal of Clinical Oncology, 1990
- Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.Journal of Clinical Oncology, 1990
- High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemiaCancer, 1987
- PERIPHERAL BLOOD STEM CELL AUTOGRAFTINGThe Lancet, 1986
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- Dose: A critical factor in cancer chemotherapyThe American Journal of Medicine, 1980